Mostrar el registro sencillo del ítem
dc.contributor.author | Kislaya, Irina | |
dc.contributor.author | Sentís, Alexis | |
dc.contributor.author | Starrfelt, Jostein | |
dc.contributor.author | Nunes, Baltazar | |
dc.contributor.author | Martínez-Baz, Iván | |
dc.contributor.author | Nielsen, Katrine Finderup | |
dc.contributor.author | AlKerwi, Ala'a | |
dc.contributor.author | Braeye, Toon | |
dc.contributor.author | Fontán-Vela, Mario | |
dc.contributor.author | Bacci, Sabrina | |
dc.contributor.author | Meijerink, Hinta | |
dc.contributor.author | Castilla, Jesús | |
dc.contributor.author | Emborg, Hanne-Dorthe | |
dc.contributor.author | Hansen, Christian Holm | |
dc.contributor.author | Schmitz, Susanne | |
dc.contributor.author | Van Evercooren, Izaak | |
dc.contributor.author | Valenciano, Marta | |
dc.contributor.author | Nardone, Anthony | |
dc.contributor.author | Nicolay, Nathalie | |
dc.contributor.author | Monge Corella, Susana | |
dc.contributor.author | VEBIS-Lot4 working group | |
dc.date.accessioned | 2023-12-29T14:49:29Z | |
dc.date.available | 2023-12-29T14:49:29Z | |
dc.date.issued | 2023-11 | |
dc.identifier.citation | Influenza Other Respir Viruses. 2023 Nov;17(11):e13195. | es_ES |
dc.identifier.uri | http://hdl.handle.net/20.500.12105/16894 | |
dc.description.abstract | Background: Within the ECDC-VEBIS project, we prospectively monitored vaccine effectiveness (VE) against COVID-19 hospitalisation and COVID-19-related death using electronic health registries (EHR), between October 2021 and November 2022, in community-dwelling residents aged 65-79 and ≥80 years in six European countries. Methods: EHR linkage was used to construct population cohorts in Belgium, Denmark, Luxembourg, Navarre (Spain), Norway and Portugal. Using a common protocol, for each outcome, VE was estimated monthly over 8-week follow-up periods, allowing 1 month-lag for data consolidation. Cox proportional-hazards models were used to estimate adjusted hazard ratios (aHR) and VE = (1 - aHR) × 100%. Site-specific estimates were pooled using random-effects meta-analysis. Results: For ≥80 years, considering unvaccinated as the reference, VE against COVID-19 hospitalisation decreased from 66.9% (95% CI: 60.1; 72.6) to 36.1% (95% CI: -27.3; 67.9) for the primary vaccination and from 95.6% (95% CI: 88.0; 98.4) to 67.7% (95% CI: 45.9; 80.8) for the first booster. Similar trends were observed for 65-79 years. The second booster VE against hospitalisation ranged between 82.0% (95% CI: 75.9; 87.0) and 83.9% (95% CI: 77.7; 88.4) for the ≥80 years and between 39.3% (95% CI: -3.9; 64.5) and 80.6% (95% CI: 67.2; 88.5) for 65-79 years. The first booster VE against COVID-19-related death declined over time for both age groups, while the second booster VE against death remained above 80% for the ≥80 years. Conclusions: Successive vaccine boosters played a relevant role in maintaining protection against COVID-19 hospitalisation and death, in the context of decreasing VE over time. Multicountry data from EHR facilitate robust near-real-time VE monitoring in the EU/EEA and support public health decision-making. | es_ES |
dc.description.sponsorship | European Centre for Disease Prevention and Control, Grant/Award Numbers: ECDC/2021/018, RS/2022/DTS/24104 | es_ES |
dc.language.iso | eng | es_ES |
dc.publisher | Wiley | es_ES |
dc.type.hasVersion | VoR | es_ES |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | * |
dc.subject | COVID-19 | es_ES |
dc.subject | COVID-19-related death | es_ES |
dc.subject | SARS-CoV-2 | es_ES |
dc.subject | Cohort design | es_ES |
dc.subject | Hospitalization | es_ES |
dc.subject | Vaccine effectiveness | es_ES |
dc.subject.mesh | COVID-19 Vaccines | es_ES |
dc.subject.mesh | COVID-19 | es_ES |
dc.subject.mesh | Humans | es_ES |
dc.subject.mesh | Aged | es_ES |
dc.subject.mesh | Vaccine Efficacy | es_ES |
dc.subject.mesh | Registries | es_ES |
dc.subject.mesh | Electronics | es_ES |
dc.subject.mesh | Hospitalization | es_ES |
dc.title | Monitoring COVID-19 vaccine effectiveness against COVID-19 hospitalisation and death using electronic health registries in ≥65 years old population in six European countries, October 2021 to November 2022 | es_ES |
dc.type | research article | es_ES |
dc.rights.license | Atribución 4.0 Internacional | * |
dc.identifier.pubmedID | 38019704 | es_ES |
dc.format.volume | 17 | es_ES |
dc.format.number | 11 | es_ES |
dc.format.page | e13195 | es_ES |
dc.identifier.doi | 10.1111/irv.13195 | es_ES |
dc.contributor.funder | Unión Europea. European Centre for Disease Prevention and Control (ECDC) | es_ES |
dc.description.peerreviewed | Sí | es_ES |
dc.identifier.e-issn | 1750-2659 | es_ES |
dc.relation.publisherversion | https://doi.org/10.1111/irv.13195 | es_ES |
dc.identifier.journal | Influenza and other respiratory viruses | es_ES |
dc.repisalud.centro | ISCIII::Centro Nacional de Epidemiología | es_ES |
dc.repisalud.institucion | ISCIII | es_ES |
dc.rights.accessRights | open access | es_ES |